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Background: To investigate serum carcinoembryonic antigen (CEA) as a prognostic factor for rectal cancer patients
receiving pre-operative chemoradiotherapy (CRT).
Methods: Between 2000 and 2009, 138 patients with advanced rectal cancer receiving CRT before surgery at our
hospital were retrospectively classified into 3 groups: pre-CRT CEA <6 ng/ml (group L; n = 87); pre-CRT CEA ≥
6 ng/ml and post-CRT CEA <6 ng/ml (group H-L; n = 32); and both pre- and post-CRT CEA ≥ 6 ng/ml (group H-H;
n = 19). CEA ratio (defined as post-CRT CEA divided by pre-CRT CEA), post-CRT CEA level and other factors were
reviewed for prediction of pathologic complete response (pCR).
Results: Five-year disease-free survival (DFS) was better in groups L (69.0%) and H-L (74.5%) than in group H-H
(44.9%) (p = 0.024). Pathologic complete response was observed in 19.5%, 21.9% and 5.3% of groups L, H-L and H-H
respectively (p = 0.281). Multivariate analysis showed that ypN stage and pCR were independent prognostic factors
for DFS and that post-CRT CEA level was independently predictive of pCR. As a whole, post-CRT CEA <2.61 ng/ml
predicted pCR (sensitivity 76.0%; specificity 58.4%). For those with pre-CRT CEA ≥6 ng/ml, post-CRT CEA and CEA
ratio both predicted pCR (sensitivity 87.5%, specificity 76.7%).
Conclusions: In patients with pre-CRT serum CEA ≥6 ng/ml, those with “normalized” CEA levels after CRT may have
similar DFS to those with “normal” (<6 ng/ml) pre-CRT values. Post-CRT CEA level is a predictor for pCR, especially in
those with pre-CRT CEA ≥6 ng/ml.
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Rectal cancer is one of the leading causes of cancer deaths
in the world [1]. For locally advanced rectal cancer, pre-
operative chemoradiotherapy (CRT) followed by radical
surgery is a standard treatment [2-4]. Pre-operative CRT
can improve locoregional tumor control, downstage the* Correspondence: lwwang@vghtpe.gov.tw
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reproduction in any medium, provided the ortumor and increase the probability of sphincter-sparing
surgery [2-6]. The response of tumors to CRT varies bet-
ween different patients. Tumor regression grade (TRG) is
widely used to determine the tumor response to CRT in
pathology [7-10]. Pathologic complete response (pCR)
could be observed in 8%–25% of certain patients after
regular doses of pre-operative CRT [2,3,5,6]. However,
TRG and pCR can only be determined microscopically
after surgery. A useful predictive model for the response
of rectal cancer to pre-operative CRT has not yet been
well established.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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measured in pre-treatment workups for rectal cancer
patients [11]. The prognostic value of serum CEA levels
has been widely discussed in the relevant literature: poor
tumor response to CRT and an increased risk of recur-
rence have been observed in patients with elevated CEA
levels before or after CRT [12-15]. It has also been
reported that the reduction ratio of pre- to post-CRT
serum CEA levels may be a prognostic factor for
disease-free survival in rectal cancer patients with a pre-
CRT CEA of more than 6 ng/ml [16]. However, it is
rarely reported whether the clinically derived CEA
parameters (including CEA reduction ratio) are cor-
related to pCR obtained after surgery. The purpose of
this study is to evaluate the significance of serum CEA
levels before treatment and their subsequent changes in
predicting clinical outcomes and pathologic tumor
responses for patients with rectal cancer receiving pre-
operative CRT.Methods
Patients
This study was approved by the institutional review board
of Taipei Veterans General Hospital (No. 2011-05-0041C).
Between May 2000 and July 2009, 191 patients with
histologically confirmed rectal adenocarcinomas, either
locally advanced disease (clinical T3, T4 or node-positive
disease by AJCC staging system) or low seated primary
T2 disease (<6 cm from anal verge), were treated with
pre-operative CRT followed by radical surgery at Taipei
Veterans General Hospital. The Eastern Cooperative On-
cology Group (ECOG) performance score of all the patients
was 0–2.
Among the 191 patients, 30 were excluded because of
missing CEA levels after CRT; 20 were excluded due to
CEA levels before or after CRT measured by enzyme
immunoassay (EIA); and a further 3 receiving transanal
excision instead of radical proctectomy were also ex-
cluded. The remaining 138 patients undergoing radical
proctectomy with serum CEA levels measured both before
and after CRT by means of radioimmunoassay (RIA)
(CEA-RIACTW; CIS bio international, Gif-sur-Yvette,
France), were included in this study.
Before CRT, computed tomography (CT) scans or
magnetic resonance imaging (MRI, 1.5-T Siemens Vi-
sion scanner with pelvic array coil and intrarectal
tube) and proctoscopy were used to evaluate the pri-
mary disease and clinical lymph node status; chest X-
rays and abdominal ultrasonography were used for
systemic evaluation. Among the 138 patients included
in this study, pelvic CTs were done before CRT in 61
patients, and pelvic MRI s were done on the other 77
patients.Treatment
The detail of CRT in the protocol was described in our
previous publication [6]. The prescription dose to whole
pelvis was 45 Gy in 20 fractions over 4 weeks. For pri-
mary T4 disease only, a boost of 5.4 Gy in 3 fractions to
the gross rectal tumors with a 1.5 cm margin followed
pelvic irradiation. The median RT duration was 26 days.
Oral chemotherapy agents, tegafur-uracil (UFUR; TTY
Biopharm, Taipei, Taiwan) 200 mg/m2/day and leuco-
vorin (Wyeth Lederle Laboratories, Taipei, Taiwan)
45 mg/day, were administered concurrently with RT
(days 1–28) and after completion of RT (days 36–63;
dose of tegafur-uracil adjusted to 250 mg/m2/day). The
total daily doses of both drugs were divided into three
doses per day.
At a median interval of 6.3 weeks (range, 3.4–12.4 weeks)
after completion of RT, radical proctectomy with total
mesorectal excision (TME) for rectal cancer was imple-
mented. Lower anterior resection (LAR) was performed in
114 patients (82.6%) and abdominoperineal resection
(APR) in 24 (17.4%), as indicated.
According to physicians’ suggestions and patients’
decisions, post-operative 5-fluorouracil based chemothe-
rapy was implemented in 71.8% of the patients with
pathologic stage III-IV and in 23.2% of the patients with
pathologic stage 0-II.
Carcinoembryonic antigen (CEA)
Serum CEA levels before CRT (pre-CRT CEA) were
measured around one week before CRT, and Serum CEA
levels after CRT (post-CRT CEA) were measured within
one week prior to surgery. In our hospital, the normal
limit of serum CEA measured by RIA was set as <6 ng/ml.
According to this cutoff value, all patients were classified
into 3 CEA change groups: pre-CRT CEA <6 ng/ml (group
L); pre-CRT CEA ≥6 ng/ml and post-CRT CEA <6 ng/ml
(group H-L); and both pre- and post-CRT CEA ≥6 ng/ml
(group H-H). The extent of CEA reduction was evaluated
by CEA ratio (defined as post-CRT CEA divided by pre-
CRT CEA).
Follow-up
After the completion of combined treatments, the patients
were regularly followed up with physical examinations
and measurement of serum CEA levels every 3–6 months
for the first 2 years. Follow-up colonoscopies, pelvic CT
scans, and chest radiography were also performed every
6–12 months for at least 5 years. In this study, recurrences
were diagnosed either pathologically or radiologically.
Statistical analysis
Statistical Package for Social Sciences software (SPSS ver-
sion 17.0, Chicago, IL) was used. Chi-square test, Fisher’s
exact test, independent t-test or one-way analysis of va-
Yang et al. Radiation Oncology 2013, 8:43 Page 3 of 9
http://www.ro-journal.com/content/8/1/43riance (ANOVA) was implemented to analyze variables.
Local control (LC) and disease-free survival (DFS) from
the time of surgery were calculated by Kaplan-Meier
method, using log-rank tests for comparison. Univariate
and multivariate analysis by Cox proportional hazards
model or logistic regression were performed. Receiver
operating characteristic curves (ROC), involving the
Youden index (maximum [sensitivity + specificity - 1]),
were used to determine optimal cutoff values. A p-values
<0.05 (two-sided test) was considered significant.
Results
Overall characteristics of the patients
Of the 138 patients, 98 (71%) were males. The mean age
was 63 (range 33–83 years), and mean pre- and post-
CRT CEA levels (ng/mL) were 13.2 (range, 1.3–400.0)
and 3.7 (range, 0.4–39.5) respectively. Free resection
margin were found in all surgical specimens. Twenty-
five patients (18%) achieved pCR after CRT. The median
follow-up time from the start of RT was 59 months
(range, 3–141 months).
Clinicopathologic features, local control and disease-free
survival of patients with reference to CEA change groups
According to pre- and post-CRT CEA levels, 138 patients
in this study were retrospectively categorized into 3 CEA
change groups as previously defined: group L (n = 87),
group H-L (n = 32) and group H-H (n = 19). The mean
pre-CRT CEA levels (ng/ml) were 3.2 (range, 1.1–6.0),
33.7 (range, 6.3–400.0) and 24.6 (range, 6.4–110.0) for
group L, group H-L and group H-H respectively; the mean
post-CRT CEA levels (ng/ml) were 2.6 (range, 0.4–7.3), 3.3
(range, 0.8–5.9) and 9.3 (range, 6.1–39.5) for group L,
group H-L and group H-H respectively. Only 1 patient in
group L had a post-CRT CEA of more than 6 ng/ml
(7.3 ng/ml). The clinicopathologic features between the 3
groups are shown in Table 1, The median follow-up time
from the start of RT was 60 months (range, 8–141 -
months), 58 months (range, 10–127 months) and 49 -
months (range, 3–124 months) for group L, group H-L
and group H-H respectively.
The 5-year LC rate was 97.5% in group L, which was sig-
nificantly better than the 86.8% in group H-L and the
78.1% in group H-H (p = 0.017, Figure 1). The 5-year DFS
rate was similar in group L (69.0%) and group H-L (74.5%),
but significantly lower in group H-H (44.9%) (p = 0.024,
Figure 2). In univariate analysis, potential predictors for
DFS included ypT stage, ypN stage, pCR, and CEA change
groups. In multivariate analysis, only ypN stage and pCR
were independently predictive of DFS (Table 2).
Clinical predictors of pCR after chemoradiation
We review possible clinical parameters that may predict
pCR. In univariate logistic regression (Table 3), potentialpredictors for pCR included gender and post-CRT CEA
level. In multivariate logistic regression, post-CRT CEA
level was independently predictive of pCR, with an odds
ratio 0.605 (range, 0.412–0.890; p = 0.011). When
performing ROCs of various CEA parameters relative to
pCR (Figure 3A), post-CRT CEA level was also the only
significant predictor with area under the curve (AUC) of
0.691 (p = 0.003), and its optimal cutoff value was
2.61 ng/ml (sensitivity 76.0%; specificity 58.4%) with the
maximum Youden index (0.344). We also observed the
patients with post-CRT CEA level <2.61 ng/ml (n = 66)
had better overall survival than those with post-CRT
CEA level ≥2.61 ng/ml (n = 72) (5-years overall survival,
89.3% vs. 67.9%; p = 0.005).
For those with pre-CRT CEA <6 ng/ml (n = 87;
Figure 3B), none of the ROC curves of various CEA
parameters was significantly predictive of pCR. For those
with pre-CRT CEA ≥6 ng/ml (n = 51; Figure 3C), the
ROC curves of post-CRT CEA level and CEA ratio were
both significantly predictive of pCR with AUCs of 0.783
(p = 0.012) and 0.733 (p = 0.038), respectively.
Discussion
Serum CEA concentrations are usually measured for
rectal cancer patients. Measurement of serum CEA
levels is inexpensive, standardized for normal limit,
widely used and easily performed, as compared with
other potential prognostic markers for rectal cancer
patients, such as CA 19–9, p53, ras expression, thymi-
dine synthase, dihydropyrimidine dehydrogenase, 18q
loss of heterozygosity, deleted in colon cancer (DCC)
protein, DNA ploidy or micro-RNA signature [11,17,18].
The micro-RNA signature may be of value in predicting
pCR [18], but will need further validation. Several stud-
ies had focused on the predictive value of pre- and post-
CRT CEA levels in patients with rectal cancer receiving
pre-operative CRT [12-15,19,20]. In this study, we found
not only pre-CRT CEA levels had prognostic signifi-
cance, “normalization” of these values and CEA ratio
also predicted tumor response and may be helpful in the
design of individualized treatment for rectal cancer with
high CEA levels before treatment.
There is some controversy as to the role of pre-CRT
CEA in rectal cancer patients. It was reported that pre-
CRT CEA levels >2.5 or >5 ng/ml were associated with
poor pCR rates and poor disease-free survival on uni-
variate analysis, but not for both on multivariate analysis
[12,13]. However, in other studies, pre-CRT CEA levels
were a common predictor of downstaging, pCR and
tumor response on multivariate analysis [14,15]. As the
pre-CRT CEA levels increase, the rates of good response
might decrease. In a recent study, for pre-CRT CEA
<3, 3–6, 6–9 and >9 ng/ml, the rates of good response
were 36%, 24%, 16% and 8%, respectively [20]. On the
Table 1 Clinicopathologic features between group L, group H-L and group H-H
Group L (n = 87) Group H-L (n = 32) Group H-H (n = 19) p-value
Gender
Male 59 (67.8%) 22 (68.8%) 17 (89.5%) 0.161
Female 28 (32.2%) 10 (31.2%) 2 (10.5%)
Age (years), mean (range) 62 (33–83) 65 (42–81) 64 (44–78) 0.351
Clinical T stage
cT2 15 (17.2%) 3 (9.4%) 1 (5.3%) 0.362
cT3-4 72 (82.8%) 29 (90.6%) 18 (94.7%)
Clinical N stage
cN0 26 (29.9%) 7 (21.9%) 1 (5.3%) 0.072
cN1-2 61 (70.1%) 25 (78.1%) 18 (94.7%)
Clinical Stage Grouping
Stage I-II 24 (27.6%) 7 (21.9%) 1 (5.3%) 0.111
Stage III-IV † 63 (72.4%) 25 (78.1%) 18 (94.7%)
Pathologic T stage
ypT0, Tis, T1-2 49 (56.3%) 15 (46.9%) 6 (31.6%) 0.131
ypT3-4 38 (43.7%) 17 (53.1%) 13 (68.4%)
Pathologic N stage
ypN0 63 (72.4%) 28 (87.5%) 9 (47.4%) 0.008
ypN1-2 24 (27.6%) 4 (12.5%) 10 (52.6%)
Pathologic Stage Grouping
yp stage 0 * 19 (21.8%) 7 (21.9%) 1 (5.3%) 0.030
yp stage I-II 43 (49.5%) 21 (65.5%) 8 (42.1%)
yp stage III-IV § 25 (28.7%) 4 (12.5%) 10 (52.6%)
pCR 17 (19.5%) 7 (21.9%) 1 (5.3%) 0.281
Distance from anal verge (cm), mean (range) 6.0 (0.5–14.0) 6.5 (3.0–14.0) 6.7 (3.0–12.0) 0.388
Surgery type
APR 17 (19.5%) 4 (12.5%) 3 (15.8%) 0.655
LAR 70 (80.5%) 28 (87.5%) 16 (84.2%)
Abbreviations: pCR, pathologic complete response; APR, abdominoperineal resection; LAR, low anterior resection.
† One patient was staged as clinical stage IV due to suspected lymph nodes at the root of inferior mesenteric artery. The patient was classified into group H-H.
* Including 25 patients with ypT0N0 cM0 and another 2 patients with ypTisN0 cM0.
§ Three patients were proved to be pathologic stage IV. Two of them were classified into group L, and the other into group H-H.
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associated with decreased pCR rates and disease-free
survival on univariate and multivariate analysis [12,19].
The literature mentioned above suggests that pre- or
post-CRT CEA level 3–6 ng/ml may serve as a valuable
threshold for prognosis and prediction of pathologic
tumor response. The change of CEA levels before and
after CRT were also investigated in some Korean studies
[16,20]. Park et al. categorized locally advanced rectal
cancer patients into 3 groups according to pre- and
post-CRT CEA levels (> or ≦3 ng/ml). They concluded
that these groupings could be of clinical value as a pre-
dictor of response (TRG) to preoperative CRT and as an
independent prognostic factor. However, the idea of
CEA reduction ratio (like our CEA ratio) had not beenpreviously mentioned until Kim’s study. They also classi-
fied rectal cancer patients into 3 groups according to
pre- and post-CRT CEA levels, though with different cut
off values (> or ≦6 ng/ml), For patients with pre-CRT
CEA >6 mg/ml, they were further divided by whether
post-CRT CEA was ≥70% lower than pre-CRT CEA.
Similarly, they had a better 5-year DFS for the lower
pre-CRT group and higher pre-CRT group with a CEA
reduction ratio ≥ 70% than the other group. However,
they could not definitely explain the pathological basis
behind the CEA reduction ratio; and it was unknown
whether pCR were related to this ratio.
Our study implied that pre-CRT CEA levels may be
prognostic of local tumor control but may not be pre-
dictive of pCR. Higher pre-CRT CEA levels could be
Time Following Surgery (Months)













Group L vs. Group H-L: p=0.028
Group L vs. Group H-H: p=0.004
Group H-L vs. Group H-H: p=0.598
Number at risk
Group L         76                    42                    14                     2
Group H-L     29                    13                     5                    1 
Group H-H     11                     8                      5                 1
Figure 1 Comparison of local control between group L, H-L and H-H. Group L: pre-CRT CEA <6 ng/ml; Group H-L: pre-CRT CEA ≥6 ng/ml
and post-CRT CEA <6 ng/ml; Group H-H: both pre- and post-CRT CEA ≥6 ng/ml.
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http://www.ro-journal.com/content/8/1/43related to more advanced locoregional spread and thus
associated with poorer local control, but not necessarily
reflect sensitivity to CRT. The 5-year DFS rates of
groups L, H-L and H-H among our patients were com-
patible with the two Korean studies mentioned above.
Group H-H carried significantly higher risks of ypN1-2
disease and pathologic stage III-IV than groups L and
H-L. This could explain why group H-H had the worst
5-year DFS rate of the three groups. Both ypN stage and














Group H-L   
Group L 62 34
28 13
Group H-H 10 8
Figure 2 Comparison of disease-free survival between group L, H-L a
≥6 ng/ml and post-CRT CEA <6 ng/ml; Group H-H: both pre- and post-CRTCRT and, in our multivariate analysis, were independent
prognostic factors for DFS. Though CEA change groups
were not, this grouping made before surgery was ob-
viously related to these two parameters (Table 1). Per-
haps, the small number of patients may also make CEA
change group statistically less prognostic. Furthermore,
both ypN stage and pCR are pathologic features, limiting
their prognostic value before operation.
We tried to find a clinical parameter predicting the






Group L vs. Group H-L:  p=0.623
Group L vs. Group H-H:  p=0.014
Group H-L vs. Group H-H:  p=0.020 
      1 
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4
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nd H-H. Group L: pre-CRT CEA <6 ng/ml; Group H-L: pre-CRT CEA
CEA ≥6 ng/ml.
Table 2 Univariate and multivariate analysis of predictive
factors for DFS (n = 138)
Univariate analysis
Variable No. of patients 5-year DFS (%) p value
Gender
Male 98 66.5 0.775
Female 40 68.2
Age
≤60 57 61.1 0.461
>60 81 72.0
Clinical T stage
cT2 19 82.0 0.089
cT3-4 119 64.5
Clinical N stage
cN0 34 76.0 0.235
cN1-2 104 64.0
Pathologic T stage
ypT0, Tis, T1-2 70 81.5 <0.001
ypT3-4 68 51.3
Pathologic N stage
ypN0 100 80.1 <0.001
ypN1-2 38 32.5
pCR
Yes 25 94.4 0.001
No 113 60.7
Distance from anal verge
≤6 cm 82 64.9 0.847
>6 cm 56 69.9
Surgery type
APR 24 57.6 0.346
LAR 114 69.8
CEA change groups
Group L 87 69.0 0.024
Group H-L 32 74.5
Group H-H 19 44.9
Multivariate analysis
Variable Hazard ratio 95% CI p value
Pathologic N stage
ypN0 1
ypN1-2 3.300 1.840–5.916 <0.001
pCR
Yes 1
No 8.502 1.143–63.228 0.037
Abbreviations: DFS, disease-free survival; CI, Confidence interval; pCR,
pathologic complete response; CRT, chemoradiotherapy; RT, Radiotherapy;
CEA, carcinoembryonic antigen.
Table 3 Univariate and multivariate analysis of predictive
factors for pCR (n = 138)
Univariate analysis
Variable Odds ratio 95% CI p-value
Gender
Male 0.357 0.146–0.872 0.024
Female 1
Age 1.016 0.979–1.054 0.403
Clinical T stage
cT2 1.244 0.375–4.129 0.721
cT3-4 1
Clinical N stage
cN0-1 0.527 0.167–1.661 0.274
cN2 1
Clinical stage grouping
Stage I-II 0.578 0.183–1.829 0.351
Stage III-IV † 1
Distance from anal verge 0.949 0.794–1.136 0.571
RT-surgery interval 1.028 0.991–1.066 0.138
Pre-CRT CEA level 1.009 0.997–1.020 0.152
Post-CRT CEA level 0.676 0.478–0.955 0.026
CEA change groups
Group L 4.371 0.545–35.069 0.165
Group H-L 5.040 0.569–44.636 0.146
Group H-H 1
CEA ratio 0.923 0.290–2.938 0.892
Multivariate analysis
Variable Odds ratio 95% CI p-value
Post-CRT CEA level 0.605 0.412–0.890 0.011
Abbreviations: pCR, pathologic complete response; CRT, chemoradiotherapy;
CEA, carcinoembryonic antigen; CI, confidence interval; RT, radiotherapy.
† One patient was staged as clinical stage IV due to suspected lymph nodes at
the root of inferior mesenteric artery.
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we found male gender was a negative predictor for pCR
in univariate analysis, although not anymore in multi-
variate analysis. Post-CRT CEA level was the only inde-
pendent predictor for pCR in our data. By using ROC
curves, post-CRT CEA level was a better predictor than
pre-CRT CEA level or CEA ratio (Figure 3A), and the
optimal cutoff value of post-CRT CEA was 2.61 ng/ml.
However, when restricting to those with pre-CRT CEA
<6 ng/ml, this observation was weakened and not
statistically valuable (Figure 3B). On the other hand, for
those with pre-CRT CEA ≥6 ng/ml, the AUC was even
larger for post-CRT CEA level to predict pCR, and CEA
ratio had value as good as post-CRT CEA level did
(Figure 3C). This suggested that the pathologic tumor
response was related to post-CRT CEA levels rather than
AROC curves relative to pCR 
(all patients; n=138)
1 - Specificity
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Figure 3 Receiver operating characteristic curves of various CEA parameters relative to pathologic complete response. (A) For all
patients (n = 138), the area under the curves (AUCs) were 0.575 (p = 0.243), 0.691 (p = 0.003) and 0.508 (p = 0.894) for pre-CRT CEA, post-CRT CEA and
CEA ratio, respectively. (B) For those with pre-CRT CEA <6 ng/ml (n = 87), the AUCs were 0.617 (p = 0.135), 0.644 (p = 0.066) and 0.501 (p = 0.991) for pre-
CRT CEA, post-CRT CEA and CEA ratio, respectively. (C) For those with pre-CRT CEA ≥6 ng/ml (n = 51), the AUCs were 0.459 (p = 0.717), 0.783 (p = 0.012)
and 0.733 (p = 0.038) for pre-CRT CEA, post-CRT CEA and CEA ratio, respectively.
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pre-CRT CEA levels.
RT-surgery interval is a well-known predictor for tumor
response to pre-operative CRT, but we did not identify this
even in univariate analysis, which could be due to less vari-
ance of the interval in our patients. The mean RT-surgery
intervals of the patients with post-CRT CEA <2.61 ng/ml
and those with post-CRT CEA ≥2.61 ng/ml were 44.6 days
(range, 27–87) and 44.8 days (range, 24–79), respectively
(p = 0.946). The comparable results supported that post-
CRT CEA groups could predicted pCR independently. Be-
sides, when dividing all patients into two groups according
to the post-CRT CEA cutoff value 2.61 mentioned above,
lower post-CRT CEA group correlated with earlier patho-
logic stages (p = 0.031; not shown in the result section)
and better overall survival (p = 0.005).The change of serum CEA levels before and after CRT
seems to be more obvious in patients with pre-CRT
serum CEA ≥6 ng/ml than those with normal levels
(mean CEA ratio ± standard deviation, 0.36 ± 0.25 vs.
0.87 ± 0.30; p < 0.001); accordingly, a low post-CRT CEA
level or CEA ratio may represent a marked reduction of
tumor burden after CRT, especially when pre-CRT CEA
levels are higher than the normal limit. We observed
pCR may be even more predictable (larger AUC) when
using post-CRT CEA level or CEA ratio in those with
pre-CRT CEA levels ≥6 ng/ml; the optimal cutoff values
of post-CRT CEA level and CEA ratio were 2.87 ng/ml
and 0.22, respectively (not shown in the result section),
with the same sensitivity 87.5%, specificity 76.7% and
maximum Youden index (0.642). But, it was still not
reasonable to conclude that surgery could be totally
Yang et al. Radiation Oncology 2013, 8:43 Page 8 of 9
http://www.ro-journal.com/content/8/1/43omitted for those with elevated pre-CRT CEA and low
post-CRT CEA levels (i.e. low CEA ratios). We hypo-
thesized that significant CEA reduction may play a role
in supporting significant tumor regression for patients
with both high pre-CRT CEA and clinical good response
after CRT. For some highly selected cases like these,
more conservative surgery may be used to preserve the
sphincter without compromising local control [21].
In this study, all the patients were treated according to
the same treatment protocol of pre-operative CRT, which
had been proved to be effective and tolerable [6]. However,
several limitations to this study exist, including retrospec-
tive design, relatively small patient numbers, imbalance of
case numbers in different groups, variation in RT-surgery
intervals, and inconsistent principle and regimen for adju-
vant chemotherapy. Many patients were excluded due to
absence of serum CEA levels or due to different laboratory
techniques for measurement.Conclusions
In conclusion, for locally advanced rectal cancer patients
with pre-treatment CEA levels ≥6 ng/ml, “normalization”
of these values after CRT may predict similar tumor re-
sponse and DFS to that of those patients with pre-CRT
CEA <6 ng/ml. Those patients with persistent high CEA
level after CRT would have the poorest response and
worst DFS. We hypothesize that low post-CRT CEA levels
obtained before surgery may predict pCR in rectal cancer
patients receiving pre-operative CRT, while CEA ratios
may also predict pCR only in patients with pre-CRT
serum CEA ≥6 ng/ml.
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